1Associate Professor, Department of Ophthalmology, IMS and SUM Hospital, Siksha’ O’ Anusandhan University, Bhubanesswar, Odisha, India
2Fellow, Vitreo-Retina Department, Sushrut eye Foundation and Research centre, Kolkota, India
3Fellow, Vitreo-retina Services, Sushrut eye Foundation and Research centre, Kolkota, India
Online published on 13 December, 2018.
The present article retrospectively elaborates the indication and the final visual acuity at 1 year in a cohort of 28 patients administered with 1 or more doses of 0.7 mg intravitrealozurdex over a period of 1 year. Data of 28 eyes of 28 patients was retrived from the medical record division. Majority of the patients were in the age group of 50–60 years. The most common indication was vascular occlusion (n=15) followed by post cataract extraction (n=7), diabetic macular edema (n=6). 5 patients had raised IOP one-two months following injection. 19 pts had prior intravitrealantiVEGF injection. 2 patients repeatedozurdex injection at 6 months. There was a difference of 173 +/-90.5 (p<0.0001)in the 1 year CRT value.
Dexamethasone implant, diabetic macular edema, vascular occlusion, central retinal thickness, visual acuity
